4-(4'-nitrophenyl)butyl methanesulfonate | 129090-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4'-nitrophenyl)butyl methanesulfonate
• 英文别名: 4-(p-nitrophenyl)butyl methanesulfonate；4-(4-nitrophenyl)butylmethanesulfonate；4-(4-nitrophenyl)butyl methanesulfonate；mesylate
• CAS: 129090-75-1
• 化学式: C₁₁H₁₅NO₅S
• 分子量: 273.31
• InChiKey: LXFOQDLDXLCQAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  97.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4'-nitrophenyl)butyl methanesulfonate 在 potassium tert-butylate 、 一水合肼 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 4-(p-nitrophenyl)butoxyamine hydrochloride
  参考文献：
  名称：

  1-Alkoxyamino-1-deoxy alditols, useful u.v.-absorbing derivatives of neutral and acidic oligosaccharides

  摘要：

  DOI：

  10.1016/0008-6215(90)84230-r
• 作为产物：
  描述：

  4-(4-硝基苯)丁酸 在 吡啶 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 4-(4'-nitrophenyl)butyl methanesulfonate
  参考文献：
  名称：

  DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine

  摘要：

  Two different classes of cis-diaminedichloroplatinum(II) complexes linked to the DNA-intercalating chromophore 9-anilinoacridine have been synthesized and evaluated as DNA-targeted antitumor agents. Two different Pt chelating ligands were investigated (based on 1,2-ethanediamine and 1,3-propanediamine), designed to deliver the Pt in an orientation likely to respectively enhance either intrastrand or interstrand cross-linking. Although both sets of ligands were somewhat unstable under neutral or basic conditions with respect to disproportionation, the corresponding Pt complexes, once prepared, appeared to be quite stable. All the Pt complexes were monitored for purity by TLC, HPLC, and FAB mass spectra, and the mode of Pt coordination was established by 195Pt NMR spectroscopy. The complexes appeared to cause simultaneous platination and intercalative unwinding of plasmid DNA. In vitro studies were carried out with both wild-type and cisplatin-resistant P388 cell lines. Whereas cisplatin itself and the ethylenediamine and 1,3-propanediamine complexes used as standards were about 10-fold less active against the resistant line, the ethylenediamine-linked Pt complexes showed no differential toxicity between the two lines and the propanediamine-linked complexes showed significant differentials (up to 8-fold) in favor of the cisplatin-resistant line. However, these were no greater than those shown by the unplatinated ligands themselves. The majority of the acridine complexes were inactive in vivo against the wild-type P388 leukemia. They were very insoluble, and although a suitable formulation was found, this may have been a factor. It is also possible that these compounds bind in such a way as to direct the Pt away from the major groove.

  DOI：

  10.1021/jm00173a015

文献信息

• Indole derivatives
  申请人：Friess Thomas

  公开号：US20060063812A1

  公开（公告）日：2006-03-23

  The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

  本发明涉及式I的化合物：它们的药用盐、对映体形式、二对映异构体和混合物，上述化合物的制备，含有这种化合物的组合物及其制备，以及这种化合物在控制或预防癌症等疾病中的应用。
• Integrin receptors antagonists
  申请人：Abbott GmbH & Co. KG

  公开号：US07105508B1

  公开（公告）日：2006-09-12

  The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

  这项发明涉及结合到整合素受体的新化合物，以及其制备和作为药物的用途。
• [EN] NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] NOUVEAUX DERIVES D'ANILINE, LEUR FABRICATION ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004096796A1

  公开（公告）日：2004-11-11

  Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式(I)的化合物及其药学上可接受的盐、对映体形式、二对映异构体和混合物，上述化合物的制备，含有它们的药物和其制造，以及上述化合物在控制或预防癌症等疾病中的使用。
• Aminoethylthiophene derivatives
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05208252A1

  公开（公告）日：1993-05-04

  This invention relates to aminoethylthiophene derivatives and more particularly 2-and 3-aminoethylthiophene derivatives which are useful as antiarrhythmic agents, their methods of use as antiarrhythmic agents, and novel intermediate compounds useful for preparation of the aminoethylthiophene derivatives of the invention.

  本发明涉及氨基乙基噻吩衍生物，特别是2-和3-氨基乙基噻吩衍生物，这些衍生物可用作抗心律失常剂，其用作抗心律失常剂的方法，以及用于制备本发明的氨基乙基噻吩衍生物的新型中间化合物。
• Compounds
  申请人：——

  公开号：US20040138300A1

  公开（公告）日：2004-07-15

  The present invention releates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及某些新型胍基或酰胺基酸衍生物和类似物，以及制备这些化合物的过程，在与胰岛素抵抗相关的临床情况中具有实用性，以及用于治疗的方法和含有它们的制药组合物。